0MH6 Stock Chart & Stats
€164.70
€1.60(1.01%)
At close: 4:00 PM EDT
€164.70
€1.60(1.01%)
Day’s Range― - ―
52-Week Range€116.00 - €176.60
Previous CloseN/A
Volume63.19K
Average Volume (3M)17.66K
Market Cap
€12.89B
Enterprise Value€12.99B
Total Cash (Recent Filing)€1.97B
Total Debt (Recent Filing)€963.20M
Price to Earnings (P/E)25.1
Beta0.92
Next Earnings
Feb 11, 2027EPS Estimate
7.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.20
Shares Outstanding83,814,530
10 Day Avg. Volume19,439
30 Day Avg. Volume17,661
Financial Highlights & Ratios
PEG Ratio0.78
Price to Book (P/B)2.29
Price to Sales (P/S)2.70
P/FCF Ratio9.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€148.33Price Target Upside-9.94% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering3
EPS Forecast (FY)14.34
Revenue Forecast (FY)€4.54B
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthSteady multi-year revenue expansion indicates sustained demand for Ipsen’s specialty medicines and growing commercial reach. Continued top-line growth can support investment in clinical development, lifecycle management, and commercial capabilities across oncology, rare diseases, and neuroscience.
Healthy ProfitabilityIpsen remains meaningfully profitable despite margin pressure, with a 30% EBITDA margin providing operating capacity to fund innovation and commercialization. This profitability supports resilience across its specialty portfolio and gives management flexibility to pursue durable growth opportunities.
Conservative LeverageLow leverage and a growing equity base provide Ipsen with a relatively resilient financial structure. This reduces balance-sheet strain, preserves borrowing capacity for strategic investment, and improves the company’s ability to absorb operating volatility while continuing to develop specialty medicines.
Bears Say
Margin CompressionThe substantial decline in net margin shows that revenue growth has not translated into stable profitability at prior levels. If higher costs or unfavorable product mix persist, Ipsen may have less earnings available for research, commercial investment, and shareholder returns.
Sharp Debt IncreaseThe sharp year-over-year increase in total debt weakens an otherwise conservative capital structure and raises the importance of future deleveraging or sustained cash generation. Higher obligations could constrain capital allocation if operating performance or cash conversion becomes less consistent.
Cash-Flow VolatilityThe strong 2025 cash-flow rebound is encouraging, but the prior weakness and inconsistent relationship between operating cash flow and profitability indicate execution or working-capital variability. Such volatility can complicate funding of research, acquisitions, and other long-term priorities.
Ipsen News
0MH6 FAQ
What was Ipsen’s price range in the past 12 months?
Ipsen lowest share price was €116.00 and its highest was €176.60 in the past 12 months.
What is Ipsen’s market cap?
Ipsen’s market cap is €12.89B.
When is Ipsen’s upcoming earnings report date?
Ipsen’s upcoming earnings report date is Feb 11, 2027 which is in 103 days.
How were Ipsen’s earnings last quarter?
Ipsen released its earnings results on Jul 30, 2026. The company reported €7.33 earnings per share for the quarter, beating the consensus estimate of €6.32 by €1.01.
Is Ipsen overvalued?
According to Wall Street analysts Ipsen’s price is currently Overvalued.
Does Ipsen pay dividends?
Ipsen does not currently pay dividends.
What is Ipsen’s EPS estimate?
Ipsen’s EPS estimate is 7.88.
How many shares outstanding does Ipsen have?
Ipsen has 83,814,530 shares outstanding.
What happened to Ipsen’s price movement after its last earnings report?
Ipsen reported an EPS of €7.33 in its last earnings report, beating expectations of €6.32. Following the earnings report the stock price went down -2.229%.
Which hedge fund is a major shareholder of Ipsen?
Currently, no hedge funds are holding shares in GB:0MH6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ipsen
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a inhibitor that is in phase III clinical trial for the treatment of second line follicular lymphoma; Tovorafenib that is in phase III clinical trial to treat first line pediatric Low-Grade Gliomas and is In phase II clinical trial for the treatment of relapsed/refractory pediatric Low-Grade Gliomas; and IPN01194 and IPN01195 that is in phase I to treat solid tumors. The company is also developing products for rare disease comprising Bylvay for the treatment of progressive familial intrahepatic cholestasis; Iqirvo, a peroxisome proliferator-activated receptor agonist to treat primary biliary cholangitis; NutropinAq, a liquid formulation of recombinant human growth hormone; Increlex, a recombinant human insulin-like growth factor; Fidrisertib that is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressive; Ritivixibat that is in phase II clinical trial to treat primary sclerosing cholangitis. In addition, it develops neuroscience products, such as Dysport that is in phase III clinical trial for the treatment of chronic and episodic migraine; and IPN10200 that is in phase II to treat aesthetic and therapeutic indications. The company has a partnership with Simcere Zaiming Pharmaceutical Co., Ltd. for the development of SIM0613, a protein expressed on varies tumor types and cancer-associated fibroblasts. The company was founded in 1929 and is headquartered in Paris, France.
0MH6 Stock 12 Month Forecast
Average Price Target
€148.33
▼(-9.94% Downside)